Covaxin to be evaluated as Covid-19 vaccine candidate in US: Bharat Biotech

Earlier, the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of January 31, 2022

Covaxin to be evaluated as Covid-19 vaccine candidate in US: Bharat Biotech

Representative image

Hyderabad-based Bharat Biotech said its Covid-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States.

"Ocugen, Inc (NASDAQ: OCGN) announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on the Company's Investigational New Drug application (IND) to evaluate the Covid-19 vaccine candidate, BBV152, known as Covaxin outside the United States. Ocugen, Inc is co-developing Bharat Biotech's Covaxin vaccine candidate for Covid-19 in USA and Canada," reads Bharat Biotech's statement.

Earlier, the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of January 31, 2022.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels